2021 Online, In the cloud

I-28 Fatemeh Aghai
Physiologically-based pharmacokinetic modeling of ruxolitinib and posaconazole to predict the clinically relevant CYP3A4 mediated drug-drug interaction
I-29 Laura Bem Olivo
Pharmacokinetic modeling based on physiology (PBPK): an innovative strategy for optimization of Piperacillin pharmacotherapy
I-30 Pavlos Chrysafidis
A paradigm shift in oral drug absorption: The rise of physiologically based finite time pharmacokinetic (PBFTPK) models.
I-31 Rebekka Fendt
Systematic evaluation of personalized physiologically based pharmacokinetic simulations
I-32 Angele Fleury
A physiologically-based pharmacokinetic (PBPK) model network for the prediction of CYP1A2 and CYP2C19 drug–drug–gene interactions with fluvoxamine, omeprazole, S-mephenytoin, moclobemide, tizanidine, mexiletine, ethinylestradiol and caffeine
I-33 Bart Lammens
A Physiologically Based Pharmacokinetic (PBPK) Model of Sildenafil to Predict Exposure in Pregnant Females. What is missing?
I-34 Jennifer Lang
Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions
I-35 Antonina Nikitich
Prediction of PD-L1 receptor occupancy in the tumor with PBPK/RO model of PD-L1 inhibitors
I-36 Luna Prieto Garcia
Simvastatin disposition described by physiologically based pharmacokinetics: Does choice of applied PBPK platform matter?
I-37 Javier Reig-López
Physiologically Based Pharmacokinetic Model for Atorvastatin: New Insights in Enzymatic and Transport Processes.
I-38 Mohammed Saleh
Predicting the impact of healthy aging on the brain pharmacokinetic profiles using a translational modeling approach
I-39 Ayatallah Saleh
Physiologically-based pharmacokinetic (PBPK) modelling to explore the pharmacokinetics (PK) and drug-drug interactions (DDI) potential of midazolam and 1-hydroxymidazolam: the hypothesis of lysosomal trapping
I-40 Christina Schräpel
Physiologically based pharmacokinetic (PBPK) modeling of (E)-clomiphene drug-drug-gene interactions with CYP2D6 and clarithromycin
I-41 Jennifer Tardiveau
A Physiologically Based Pharmacokinetic model to explore the blood-milk barrier in lactating species: case study with oxytetracycline
I-42 Sung-yoon Yang
Application of Physiologically Based Pharmacokinetic Modeling and Population Pharmacokinetic Modeling to predict potential Drug-Drug Interaction (DDI) between rivaroxaban and carbamazepine.